POSTPONED: 8th ESO-SIOP Europe Masterclass in Paediatric Oncology
Not eligible for ESCO credits
28.11.2020 - 03.12.2020
Bucharest, Romania
MASTERCLASS
Important information
On behalf of ESO and SIOP-Europe we would like to inform you that due to the ongoing Coronavirus (COVID-19) crisis we have made the difficult decision to postpone the 8th ESO-SIOP Europe Masterclass in Paediatric Oncology programmed for 28 November - 3 December in Bucharest, Romania.
We deeply regret having to take this decision but we feel that in the current climate we all need to do our part in trying to limit the diffusion of the virus as much as possible and this was the only decision possible considering your role in society as medical staff.
We apologize for any inconvenience caused but we think you’ll all agree that this solution was unavoidable.
The next Masterclass will be held on 27 November - 2 December 2021, in Bucharest, Romania. Further information is available HERE.
Description
Chairs: S. Bielack, DE - B. Morland, UK - C. Stefan, RO/ZA
Host Chair: M. Dragomir, RO
ESO and SIOP-Europe are pleased to announce the eighth Masterclass in Paediatric Oncology. This clinically-oriented educational programme has been designed for young paediatric oncologists, who wish to improve their skills in clinical management of common childhood tumours. It is designed to offer a unique learning experience, providing practice-oriented training and the teaching sessions will focus on the application of the most recent research findings to clinical practice.
LEARNING OBJECTIVES
• Improve knowledge in the field
• Improve skills in dealing with cancer problems as a whole
• Improve knowledge of current clinical practice and state-of-the-art treatment
MAIN TOPICS
• Bone tumours
• Central nervous system tumours
• Leukemia
• Lymphoma
• Neuroblastoma
• Rare tumours
• Soft-tissue sarcoma
• Wilms’ tumour
The Masterclass in Paediatric Oncology is an ESO-SIOP Europe joint event |
Faculty
Andishe Attarbaschi, St. Anna's Kinderspital, Dept. of Paediatrics (Vienna, AT)
André Baruchel, University Hospital Robert Debré (APHP), Pediatric Hematology-Immunology Dept., Paris, FR
Pablo Berlanga, Gustave Roussy, Dept. of Pediatric and Adolescent Oncology (Villejuif, FR)
Stefan Bielack, Klinikum Stuttgart - Olgahospital, Dept. of Pediatric Oncology, Hematology, Immunology Dpt. (Stuttgart, DE)
Gianni Bisogno, University of Padova, Dept. of Women's and Children's Health (Padova, IT)
Anca Colita, Fundeni Clinical Institute, Paediatric Hem-Onc and BMT Dept. (Bucharest, RO)
Uta Dirksen, University Hospital Essen, Dept. of Pediatrics III, Hematology/Oncology, Essen, DE
François Doz, Institut Curie, Paediatric Oncology Dpt. (Paris, FR)
Monica Desiree Dragomir, University of Medicine 'Carol Davila', Oncology Institute (Bucharest, RO)
Angelika Eggert, Charité University Medicine Berlin, Dept. of Paediatric Oncology/ Haematology (Berlin, DE)
Didier Frappaz, Centre Léon Bérard, Dept. of Adult and Paediatric Neuro-oncology (Lyon, FR)
Jacques Grill, Institut Gustave Roussy, Dept. of Paediatric and Adolescent Oncology (Villejuif, FR)
Henrik Hasle, Aarhus University Hospital, Dept. of Pediatrics (Aarhus N, DK)
Andrew Hoy, Epsom, GB
Christine Mauz-Körholz, Universitätsklinikum Giessen und Marburg, Dept. of Pediatric Hemotology and Oncology, Giessen, DE
Bruce Morland, Birmingham Children's Hospital, Oncology Dpt. (Birmingham, GB)
Daniel Orbach, Curie Institute, Paediatrics, Adolescent, Young Adults SIREDO Center (Paris, FR)
Dominik Schneider, Klinik für Kinder- und Jugendmedizin, Klinikum Dortmund (Dortmund, DE)
Thorsten Simon, University Clinic Köln, Dept. of Pediatric Oncology and Hematology (Köln, DE)
Filippo Spreafico, Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Medical Oncology (Milano, IT)
Cristina Stefan, AMRII (Cape Town, ZA)
General information
ORGANISING SECRETARIAT
Alexandra Zampetti
European School of Oncology (ESO)
Piazza Indipendenza 2
6500 Bellinzona
ph +41 91 820 09 54
e-mail: azampetti@eso.net
Applications:
Dolores Knupfer, dknupfer@eso.net, ph: +41 91 820 0952
CME ACCREDITATION AND CERTIFICATE
The 8th ESO - SIOP Europe Masterclass in Paediatric Oncology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.
The programme has been granted up to 34 European CME credits (ECMEC). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
Participants will receive their certificate of attendance via e-mail after on completion of the evaluation form.
ESCO CREDITS
Being selected to take part in an ESO Masterclass is one of the ESO activities that gives participants eligibility to enrol in ESCO - the College of the European School of Oncology.
A Masterclass also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits. Full and active participation in the Masterclass earns participants 30 ESCO credits.
Visit www.esco.org for information on how to join ESCO.
Application
PARTICIPANT’S PROFILE
• Age between 30 and 40 years
• 2-4 years’ experience in paediatric oncology
• Involvement in scientific activities and clinical trials
• Fluency in English
PARTICIPATION
Admittance to the Masterclass is by competitive application. The successful applicants are granted free registration but the cost of half-board accommodation and transfer to the course venue is EUR 450.- for the period 6-11 June 2020 and travel will be covered by the participants.
All participants will be expected to reside at the course venue and their full participation is compulsory throughout the course.
The Masterclass will be taught entirely in English and fluency in English is necessary for admission.
SCHOLARSHIPS
Four full tuition scholarships will be offered to applicants from Low and Middle Income Countries (LMIC) as defined by the World Bank. In order to be considered for a scholarship, please submit a letter of motivation requesting consideration. Please note that scholarship recipients will be responsible for arranging their own travel to Bucharest.
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
THE APPLICATION DEADLINE HAS PASSED (12 FEBRUARY 2020)
Programme
28 November
Arrival | ||
20:00 | Welcome from the Chairs followed by dinner |
29 November
8:00 | Registration |
|
8:30 | Multiple choice pre-test | |
BONE TUMOURS Session leader: B. Morland, UK |
||
9:00 | Bone sarcomas/case presentations S. Bielack, DE |
|
11:00 | Coffee break |
|
11:15 | Bone sarcomas/case presentations S. Bielack, DE |
|
12:45 | Lunch break |
|
CNS TUMOURS Session leader: M. Dragomir, RO |
||
13:45 | CNS Tumor biology TBC |
|
14:15 | Medulloblastoma F. Doz, FR |
|
14:45 | HGG and LGG J. Grill, FR |
|
15:30 | Ependymoma D. Frappaz, FR |
|
16:00 | Coffee break |
|
16:30 | Case presentations | |
19:30 |
Dinner |
30 November
RARE TUMOURS Session leader: S. Bielack, DE |
||
8:00 | Intracranial Germ Cell Tumours D. Schneider, DE |
|
8:30 | Germ Cell Tumours D. Schneider, DE |
|
9:30 | Hepatoblastoma B. Morland, UK |
|
10:30 | Very rare tumors D. Schneider, DE |
|
11:00 | Coffee break |
|
11:30 | Case presentations |
|
12:30 | Lunch break | |
13:30 | Key note lecture: T-cells TBC |
|
LEUKAEMIA Session leader: A. Colita, RO |
||
14:30 | ALL M. Schrappe, DE |
|
15:30 | Management of AML H. Hasle, DK |
|
16:30 | Case presentations | |
20:00 | Offsite dinner, Caru' cu Bere |
1 December
PARALLEL SESSIONS: |
||
8:00 | Communication workshop (RED GROUP) |
|
9:00 | Key note lecture: Early phase studies (BLUE GROUP) B. Morland, UK |
|
10:00 | Coffee break | |
SOFT TISSUE SARCOMA Session leader: C. Stefan, ZA |
||
10:30 | Rhabdomyosarcoma G. Bisogno, IT |
|
11:30 | Non Rhabdo Soft Tissue Sarcoma |
|
12:30 | Questions and discussion |
|
13:00 | Lunch break | |
14:00 | Case presentations | |
16:00 | Coffee break |
|
PARALLEL SESSIONS: | ||
16:30 | Communication workshop (BLUE GROUP) | |
16:30 | Key note lecture: Early phase studies (RED GROUP) B. Morland, UK |
|
Free evening |
2 December
LYMPHOMA Session leader: C. Stefan, ZA |
||
8:00 | Overview: Non-Hodgkin's Lymphoma A. Attarbaschi, AT |
|
9:00 | Overview: Hodgkin's Lymphoma | |
10:00 | Coffee break |
|
10:30 | Case presentations |
|
12:30 | Lunch |
|
13:30 | Keynote lecture: How to identify patients who may benefit from personalised medicine P. Berlanga, FR |
|
NEUROBLASTOMA Session leader: B. Morland, UK |
||
15:00 | Current approaches in low risk and intermediate risk neuroblastoma T. Simon, DE |
|
16:00 | Coffee break |
|
16:30 | Current approaches in high-risk and relapse neuroblastoma A. Eggert, DE |
|
19:30 | Dinner |
3 December
WILMS TUMOUR Session leader: S. Bielack, DE |
||
8:00 | Overview of renal tumours of childhood and approaches to treatment of Wilms tumour (part I) F. Spreafico, IT |
|
8:45 | Case presentations |
|
9:30 | Overview of renal tumours of childhood and approaches to treatment of Wilms tumour (part II) F. Spreafico, IT |
|
10:15 | Case presentations |
|
11:30 | Multiple choice post-test |
|
12:00 | Discussion and closure |
|
12:30 | Standing brunch | |
13:00 | Group transfer from hotel to airport |